• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Just Ask the Expert: A protocol for treating IMHA

March 1, 2011
Christopher G. Byers, DVM, DACVECC, DACVIM

Dr. Christopher Byers gives his thoughts on treating this form of anemia.

Dr. Byers welcomes critical care questions from veterinarians and veterinary technicians.

Click here to submit your question, or send an e-mail to vm@advanstar.com with the subject line "Critical care questions."

We are treating a dog in which immune-mediated hemolytic anemia was diagnosed 10 days ago. Initial treatment included prednisone and doxycycline. After five days of this treatment, the dog required a packed red blood cell transfusion, and we initiated cyclosporine, azathioprine, and aspirin. Five days after that (10 days into treatment), the dog's hematocrit is still decreasing. Is there anything else we should be doing for the patient?

A. Immune-mediated hemolytic anemia (IMHA) is most commomly a primary disease, also called idiopathic IMHA. However, one common mistake practitioners can make is not being aggressive enough in identifying any underlying causes, such as neoplasia, that may make the IMHA a secondary disease. Make sure you have thoroughly investigated this possibility. This investigation should include an extensive history and thorough diagnostic testing.

Dr. Christopher G. Byers

IMHA is a complicated disease to treat. My typical initial treatment regimen for patients with confirmed IMHA in which no underlying primary disease is found (idiopathic IMHA) is similar to yours and includes

Advertisement

1. Immunosuppressive therapy—prednisone at 30 mg/m2 /day orally; concurrent cyclosporine at 5 mg/kg every 12 hours orally or intravenously (other immunosuppressive medications to be aware of include azathioprine, mycophenolate mofetil, and leflunomide)

2. Gastroprotection—famotidine at 0.5 mg/kg orally every 12 hours

3. Immunomodulation—melatonin at 3 to 6 mg every 12 hours

4. Antimicrobial therapy—doxycycline at 5 to 10 mg/kg orally every 12 hours for 28 days

5. Antiplatelet aggregation therapy (the most common cause of morbidity and mortality in patients with IMHA is thromboembolism1 )—aspirin at 0.5 to 1 mg/kg/day orally

Also, for patients that do not seem to be responding to therapy in the first week, keep in mind that prednisone may take up to seven days to become effective. Similarly, oral cyclosporine may take up to two weeks and azathioprine up to three weeks to exert their effects. Therefore, other therapies of temporary benefit, such as administering packed red blood cells, may need to be initiated and potentially repeated while waiting for patients to respond to these immunosuppressive treatments.

In some refractory cases, I also recommend intravenous immunoglobulin G (IVIg). There is limited and mixed research regarding the efficacy of this medication in patients with IMHA, but my anecdotal experience has been positive. The protocol I use is to infuse 0.5 g/kg intravenously over three to four hours for three consecutive days. Unfortunately, IVIg is a relatively expensive medication, and with limited proven efficacy, it may be hard to justify the expense.

There is an unfortunate lack of prospective research in our companion-animal species regarding the optimal immunosuppressive protocol, and each clinician seems to have his or her own preferences. The protocol detailed above has generally worked well for me, but as anyone who has been in practice for a while can attest, IMHA can truly be a frustrating disease to adequately control.

Christopher G. Byers, DVM, DACVECC, DACVIM

VCA Veterinary Referral Associates

500 Perry Parkway

Gaithersburg, MD 20877

REFERENCE

1. Weinkle TK, Center SA, Randolph JF, et al. Evaluation of prognostic factors, survival rates, and treatment protocols for immune-mediated hemolytic anemia in dogs: 151 cases (1993-2002). J Vet Med Assoc 2005;226(11):1869-1880.

Related Content:

Clinical
Free microchipping event to take place in Chicago
Free microchipping event to take place in Chicago
Morris Animal Foundation funds study on environmental toxins and lymphoma
Morris Animal Foundation funds study on environmental toxins and lymphoma
Study evaluating potential treatment for degenerative myelopathy receives funding
Study evaluating potential treatment for degenerative myelopathy receives funding

Advertisement

Latest News

Research reveals efficacy of non-surgical contraceptive alternative for cats

Potential blood transfusion may offer lion chance of survival

Keeping pets safe from wildfire smoke

New report links pet ownership with human health care savings

View More Latest News
Advertisement